Loading
Everything OnCo dates to 2020: 793 entries, 208 papers, 186 papers listed on people's pages, 131 landmarks and 107 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
793 dated entries in OnCo fall in 2020: 208 papers, 186 papers listed on people's pages, 131 landmarks, 107 trials reported, 79 approvals, 36 regulatory events, 19 financing rounds, 10 companies founded, 8 technologies, 7 guideline changes and 2 journals founded.
Of those, 30 to the day, 13 to the month and 750 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Advanced medullary thyroid cancer
Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide. TA638, published 1 July 2020, only at ECOG performance status 0 or 1 (IMpower133).
Triple-negative unresectable locally advanced or metastatic breast cancer with PD-L1 of 1 percent or more, with nab-paclitaxel, untreated for metastatic disease; NICE TA639 (1 July...
EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy
EU brand Ayvakyt
Unresectable/metastatic GIST with PDGFRA exon 18 mutation including D842V
Maintenance after first-line platinum in advanced urothelial cancer
Newly diagnosed AML unfit for intensive chemotherapy, with venetoclax (VIALE-A)
Oral azacitidine (Onureg) maintenance after intensive induction (QUAZAR AML-001)
Relapsed myeloma ≥4 lines (accelerated; withdrawn 2022)
First-line maintenance with olaparib in HRD-positive ovarian cancer
Olaparib in germline BRCA-mutated metastatic castration-resistant prostate cancer
MCL after ≥2 lines including a BTK inhibitor
Relapsed/refractory mantle cell lymphoma
First-line ALK-positive metastatic NSCLC
MET exon 14 skipping NSCLC (capmatinib; tepotinib 2021)
Metastatic NSCLC with a MET exon 14 skipping mutation (accelerated approval)
BRAF V600E mCRC with encorafenib
Unresectable locally advanced or recurrent head and neck cancer (conditional)
MRD in chronic lymphocytic leukaemia
With atezolizumab and vemurafenib in BRAF V600 melanoma
MDS and CMML
BRAF V600E mCRC with cetuximab, previously treated
ALK-positive NSCLC after crizotinib
NTRK fusion-positive solid tumours, including colorectal cancer. TA644, published 12 August 2020, withdrawn: replaced by TA1118, which NICE terminated on 7 January 2026 with no com...
ROS1-positive advanced non-small-cell lung cancer in patients who have not had a ROS1 inhibitor. TA643, published 12 August 2020, subject to the commercial arrangement.
Same
NTRK fusion-positive solid tumours: NICE TA644 (12 August 2020) recommended entrectinib within the Cancer Drugs Fund; it was replaced by TA1118 (terminated appraisal, 7 January 202...
Detection of ER-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer
Same (Cu-64 DOTATATE)
PSMA PET (UCLA/UCSF NDA); kits 2021-2022
Same
Companion diagnostic for osimertinib (EGFR) in NSCLC; first liquid comprehensive genomic profiling test
HER2-positive metastatic breast cancer after chemotherapy, with vinorelbine
Relapsed myeloma with pomalidomide-dexamethasone; 2021 with carfilzomib-dexamethasone
NTRK fusion-positive solid tumours, including colorectal cancer. TA630, published 27 May 2020: recommended for use within the Cancer Drugs Fund only, under a managed access agreeme...
NTRK fusion-positive solid tumours in adults and children, locally advanced or metastatic or where surgery would cause severe morbidity, with no satisfactory treatment options: NIC...
ALK-positive advanced non-small-cell lung cancer progressing after alectinib or ceritinib as the first ALK inhibitor, or after crizotinib and at least one other ALK inhibitor.
Metastatic SCLC after platinum chemotherapy (accelerated)
MDS-RS and beta-thalassaemia
Very low- to intermediate-risk MDS with ring sideroblasts after ESA failure
HER2+ metastatic breast cancer after ≥2 anti-HER2 regimens, with chemotherapy
Low-grade upper tract urothelial carcinoma (mitomycin pyelocalyceal gel)
Companion diagnostic for olaparib plus bevacizumab first-line maintenance in HRD-positive ovarian cancer
Relapsed/refractory high-risk neuroblastoma in bone or bone marrow with partial response, minor response or stable disease, with GM-CSF (accelerated)
HER2+ metastatic breast cancer with capecitabine after ≥2 anti-HER2 regimens
First-line ovarian maintenance
Locally advanced or metastatic squamous non-small-cell lung cancer after chemotherapy. TA655, published 21 October 2020, stopped at 2 years of uninterrupted treatment and only for...
Maintenance treatment of germline BRCA1/2-mutated metastatic pancreatic adenocarcinoma that has not progressed after at least 16 weeks of platinum-based first-line chemotherapy; li...
RET fusion companion claim (pralsetinib)
CE mark
Relapsed or refractory CLL/SLL; relapsed or refractory mantle cell lymphoma
Endogenous Cushing's syndrome in adults
Cushing's disease in adults for whom pituitary surgery is not an option or has not been curative
Untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer. TA654, published 14 October 2020, recommends osimertinib within its marketing authorisat...
EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer after a first-line EGFR inhibitor.
Adjuvant EGFR-mutant NSCLC
Triple-negative breast cancer, CPS ≥10 (pembrolizumab plus chemotherapy)
Metastatic TNBC, PD-L1 CPS ≥10, with chemotherapy
Previously treated FGFR2-fusion/rearranged cholangiocarcinoma (accelerated)
Phesgo subcutaneous fixed-dose combination with trastuzumab
Kaposi sarcoma (AIDS-related after ART failure; HIV-negative)
RET-fusion metastatic NSCLC (full approval 2023)
Advanced prostate cancer
Advanced GIST after ≥3 prior kinase inhibitors including imatinib
Advanced hepatocellular carcinoma after prior systemic therapy
BRCA-mutated mCRPC after ARPI and taxane
Metastatic TNBC, ≥2 prior lines (accelerated; full 2021)
Relapsed/refractory DLBCL; myeloma with bortezomib after ≥1 line
RET-fusion NSCLC and thyroid; RET-mutant MTC
NF1 with symptomatic, inoperable plexiform neurofibromas, children 2 and over (extended to adults and to age 1 and over in 2025)
Chronic weight management in obesity due to POMC, PCSK1 or LEPR deficiency
Advanced non-pancreatic neuroendocrine tumours; pancreatic neuroendocrine tumours from 2021
R/R DLBCL with lenalidomide, transplant-ineligible (accelerated)
Epithelioid sarcoma; relapsed FL (EZH2-mutant after 2 lines; wild-type without alternatives). Withdrawn March 2026
Unresectable advanced or recurrent NSCLC with MET exon 14 skipping
therascreen BRAF V600E: encorafenib plus cetuximab in colorectal cancer
510(k) clearance, digital breast tomosynthesis
HER2+ metastatic breast cancer including brain metastases, with trastuzumab and capecitabine
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Accelerated approval, epithelioid sarcoma
Medicare coverage (MolDX) for stage II-III colorectal cancer
Extensive-stage SCLC with chemotherapy (CASPIAN)
With encorafenib for BRAF V600E mCRC (BEACON)
BRAF V600E metastatic CRC with cetuximab after prior therapy (BEACON)
HER2+ metastatic breast cancer including brain metastases, with trastuzumab and capecitabine (HER2CLIMB)
Accelerated approval, metastatic TNBC after ≥2 prior therapies
First-line ovarian maintenance, all-comers (PRIMA)
Subcutaneous Darzalex Faspro
With olaparib as HRD-positive maintenance (PAOLA-1)
Accelerated approval, RET-fusion NSCLC and thyroid cancer, RET-mutant MTC (LIBRETTO-001)
With nivolumab in first-line NSCLC (CheckMate 227) and HCC
INVICTUS
HRR-mutant mCRPC (PROfound)
Unresectable HCC with bevacizumab (IMbrave150)
TMB ≥10 mut/Mb companion claim for pembrolizumab
Accelerated approval, second-line SCLC
TMB-high solid tumours (tumour-agnostic)
Accelerated approval, follicular lymphoma
Phesgo SC
Phesgo (pertuzumab, trastuzumab, hyaluronidase) subcutaneous
MDS/CMML
L-MIND accelerated approval
Accelerated approval, relapsed/refractory myeloma after ≥4 lines (DREAMM-2)
FoundationOne Liquid CDx approved
Breakthrough Therapy designation, HER2+ urothelial cancer
Onureg maintenance in AML
World-first approval of a photoimmunotherapy drug
With nivolumab in mesothelioma (CheckMate 743)
Venetoclax + azacitidine full approval in unfit AML (VIALE-A)
Full approval in AML (VIALE-A)
Metastatic TNBC, PD-L1 CPS ≥10, with chemotherapy (KEYNOTE-355)
Accelerated approval (Study 201, 12-230)
RxPONDER extends to 1-3 positive nodes (postmenopausal)
Breakthrough Therapy designation
Adjuvant EGFR-mutant NSCLC after resection (ADAURA)
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
1 row added. Anchored to FDA approval of tucatinib, April 2020 (HER2CLIMB).
1 row added. Anchored to FDA approvals of first-line maintenance olaparib (December 2018, SOLO-1), niraparib (April 2020, PRIMA) and olaparib with bevacizumab (May 2020, PAOLA-1).
2 rows added. Anchored to Annals of Oncology publication, 2020.
2 rows added. Anchored to FDA accelerated approval of enfortumab vedotin (December 2019) and approval of avelumab maintenance (June 2020, JAVELIN Bladder 100).
1 row added, 1 row recategorised. Anchored to FDA approvals of encorafenib with cetuximab (April 2020, BEACON) and first-line pembrolizumab for MSI-high disease (June 2020, KEYNOTE...
2 rows added. Anchored to Annals of Oncology publication, 2020.
2 rows added. Anchored to FDA accelerated approval of sacituzumab govitecan (April 2020) and approval of pembrolizumab with chemotherapy for PD-L1 CPS 10 or above (November 2020, K...
The year reported on trial records, with the headline result the record gives.
Bortezomib added to chemotherapy did not improve three-year event-free survival (44.8 percent against 47.0 percent) and added toxicity; sorafenib for high allelic ratio FLT3-ITD di...
Hazard of an event 0.43 compared with the historical cohort in children under 36 months (p < 0.0005); four-year event-free survival 37 percent and overall survival 43 percent for a...
Week-48 progression-free survival 50 percent with paclitaxel against 20 percent with oral etoposide, and 64 percent against 44 percent with bleomycin plus vincristine; both investi...
OS HR 0.49.
Recruitment closed March 2020; the mortality endpoint is not due until the trial ends in December 2031 (ISRCTN33292440).
Event-free survival hazard ratio 0.95 (95 percent confidence interval 0.75 to 1.21, p=0.70) for adjuvant against early salvage radiotherapy, a 1 percentage point difference at 5 ye...
OS 12.1 vs 6.7 months, HR 0.48.
Zanubrutinib did not significantly increase the complete or very good partial response rate over ibrutinib, but had markedly less cardiovascular and other toxicity; approved for Wa...
Genomic assignment within seven days was feasible; patients treated on Beat AML sub-studies had median overall survival of 12.8 months against 3.9 months for those choosing standar...
PFS 14.5 vs 12.6 months (HR 0.71, p 0.0016); final OS 32.4 vs 28.2 months (HR 0.92, p 0.43). Not licensed.
Cabozantinib met the activity thresholds in both the Ewing sarcoma and osteosarcoma cohorts.
Colorectal cancer in 9 percent of participants on aspirin against 13 percent on placebo over ten years (hazard ratio 0.65, p 0.035); hazard ratio 0.56 among those who completed two...
OS 9.8 vs 10.0 months, HR 1.04 (95% CI 0.83-1.30); no benefit.
Neoadjuvant nivolumab produced pathological complete responses in a substantial share of resectable Merkel cell carcinomas, with durable responses; nivolumab also showed activity i...
CPS ≥5: OS 14.4 vs 11.1 months (HR 0.71); 5-year OS 16% vs 6%.
OS 18.1 vs 14.1 months, HR 0.74; 5-year OS 14% vs 6%.
PFS HR 0.51; OS HR 0.77 at ~4 years (46.5 vs 36.0 months).
Median overall survival 14.1 against 10.7 months at the interim analysis (hazard ratio 0.69, p=0.00065), and 15.6 against 10.9 months with longer follow-up.
PFS HR 0.37; crossover-adjusted OS HR 0.49.
Nelarabine improved disease-free survival in T-cell acute lymphoblastic leukaemia, and Capizzi methotrexate outperformed high-dose methotrexate.
5-year PFS 60% vs 8%, HR 0.19 (JCO 2024).
18-month OS 95%, DFS 88%.
Neuroendocrine cohort: about one in four responded, concentrated in high-grade disease; angiosarcoma cohort about one in four, mostly cutaneous scalp and face tumours; many other c...
OS 53.7 vs 46.0 months (HR 0.75).
Higher objective response rate and longer overall survival with trastuzumab deruxtecan than with irinotecan or paclitaxel; approved in January 2021.
6-month PFS 20% vs 16%; median OS 11.1 vs 10.5 months; no benefit.
EFS HR 0.71; OS HR 0.62 favouring VDC/IE.
At ten years, 28.5 Gy in five once-weekly fractions gave normal-tissue effects no worse than 50 Gy in twenty-five (odds ratio 1.22, 0.87 to 1.72), while 30 Gy was worse (2.12, 1.55...
5-year ipsilateral breast tumour relapse 1.4% (26 Gy in 5) vs 2.1% (40 Gy in 15), non-inferior.
ORR 37%; PFS 7.0 months; OS 17.5 months.
Dostarlimab produced durable objective responses in roughly four in ten patients with mismatch repair-deficient recurrent endometrial cancer; accelerated approval in April 2021.
PFS 16 vs 8 months (HR 0.51); OS not reached vs 17 months (HR 0.45).
DFS HR 0.82 (0.63 to 1.06), p 0.136, not significant; non-basal subgroup DFS HR 0.53 vs basal 0.94 (interaction p 0.069).
Response rate 68% (treatment-naive, n=28) and 41% (previously treated, n=69) in MET exon 14 skipping disease; about a third in high-level MET amplification.
Five-year event-free survival 92 percent with adjuvant against 90 percent with salvage radiotherapy (hazard ratio 0.81, 95 percent confidence interval 0.48 to 1.36); late grade 2 o...
Median overall survival 11.2 months with PEGPH20 plus nab-paclitaxel and gemcitabine against 11.5 months with placebo (hazard ratio 1.00, 95 percent confidence interval 0.80 to 1.2...
Sustained castration through 48 weeks in 96.7 against 88.8 percent (difference 7.9 percentage points, 95 percent confidence interval 4.1 to 11.8, superior, p<0.001); castrate testo...
Breast cancer in 85 of 1,920 on anastrozole against 165 of 1,944 on placebo after a median 131 months, hazard ratio 0.51 (Lancet 2020).
OS 19.2 vs 13.4 months, HR 0.66.
Pathological complete response 58% vs 41% (all patients); 69% vs 49% in PD-L1-positive disease.
PFS HR 0.82 (not significant); OS trend unfavourable; US indication withdrawn 2021.
In the PD-L1-highest subgroup, median overall survival 20.2 against 13.1 months (hazard ratio 0.59, p=0.01).
Atezolizumab added to vemurafenib and cobimetinib prolonged investigator-assessed progression-free survival in BRAF V600-mutant melanoma, without an overall survival benefit; appro...
3-year EFS 93.9% vs 82.3%, HR 0.32; OS also improved.
Response rate 57 percent with cisplatin-fluorouracil against 59 percent with carboplatin-paclitaxel; serious adverse events 62 against 36 percent; median overall survival 12.3 agai...
PFS HR 0.15; OS HR 0.36.
OS 21.4 vs 14.3 months, HR 0.69.
PFS HR 1.21; futility.
Pembrolizumab produced complete responses in a substantial minority of patients with BCG-unresponsive carcinoma in situ, about half of them lasting a year or more; approved in Janu...
Pembrolizumab alone was non-inferior to chemotherapy for overall survival in PD-L1-positive disease; pembrolizumab plus chemotherapy was not superior to chemotherapy; large benefit...
Biliary cohort ORR 5.8% (6/104); median OS 7.4 months; median PFS 2.0 months; median duration of response not reached.
PFS 16.5 vs 8.2 months (HR 0.60); 5-year OS 54.8%, median OS 77.5 months.
PFS 13.2 vs 8.3 months, HR 0.65.
OS HR 0.73 in CPS ≥10.
EFS HR 0.63; OS HR 0.66 (5-year); 7-year OS 85.1% vs 77.2%.
OS 12.4 vs 9.8 months (HR 0.73); 5-year OS HR 0.72.
Objective response 34% in recurrent or metastatic disease and 50% in locally advanced disease.
ORR 60%, CR 43%.
Genotype-matched targeted arms (taselisib, palbociclib, AZD4547) closed for futility; nivolumab plus ipilimumab did not beat nivolumab (S1400I); ramucirumab plus pembrolizumab impr...
Objective response 35.2 percent (37 of 105); grade 3-4 neutropenia in 46 percent.
Luspatercept produced transfusion independence for eight weeks or longer in significantly more patients than placebo; approved in April 2020.
iDFS HR 0.68.
Day-28 overall response 70.4% in 54 treated children, above the prespecified 45% historical control; overall survival 74.1% at day 100 and 68.5% at day 180.
Neratinib plus capecitabine improved progression-free survival over lapatinib plus capecitabine and reduced interventions for central nervous system disease; approved in February 2...
Most of the 22 biomarker-drug cohorts did not meet their pre-set efficacy thresholds; the trial demonstrated national molecular screening and the limits of single-agent matching.
Very high, durable response rate in PDGFRA D842V-mutant GIST; approved for that indication in January 2020.
ORR 50%.
5,954 patients enrolled; 17.8 percent assigned to an arm. Dabrafenib plus trametinib in BRAF V600 tumours (38 percent response) and nivolumab in dMMR non-colorectal tumours (36 per...
Median overall survival 55.4 months with cetuximab against 81.0 months without (hazard ratio 1.45).
Cognitive failure hazard ratio 0.74 with hippocampal avoidance; no difference in intracranial control or survival.
Median OS 7.5 vs 6.1 months, HR 0.773; grade 3+ adverse events 19% vs 30%.
PFS 8.9 vs 5.0 months, HR 0.482.
Progression at 6 months 19 percent after stereotactic ablative radiotherapy against 61 percent under observation (p=0.005); total consolidation of PSMA-avid disease reduced new les...
PFS 5.9 vs 4.2 months (HR 0.74); OS 19.1 vs 12.6 months (HR 0.61, p 0.04); PIK3CA/AKT1/PTEN-altered PFS 9.3 vs 3.7 months (HR 0.30). Not confirmed by CAPItello-290.
PALLAS iDFS HR 0.96; PENELOPE-B iDFS HR 0.93; both null.
Median overall survival 17 months from diagnosis (95 percent confidence interval 15 to 19) and 10 months from electroporation in locally advanced disease; local recurrence 46 perce...
Circulating tumour DNA matched tissue genotyping with about 93 percent sensitivity; neratinib (HER2 mutations) and capivasertib plus fulvestrant (AKT1 mutations, receptor-positive)...
rPFS HR 0.34; OS HR 0.69 (cohort A).
Three-year disease-free survival 44 percent with second-look surgery and HIPEC against 53 percent with surveillance.
Accuracy 92% vs 65%.
By 36 months, complete haematological response with improved disease burden and molecular response were both more frequent with ropeginterferon than hydroxyurea.
Median overall survival 24.7 months with oral azacitidine against 14.8 months with placebo (hazard ratio 0.69); approved in the United States in September 2020.
Five-year biochemical progression-free survival 85 percent with adjuvant against 88 percent with early salvage radiotherapy (hazard ratio 1.10, 95 percent confidence interval 0.81...
3-year disease-related treatment failure 23.7% vs 30.4%; pathological complete response 28% vs 14%.
Five-year freedom from biochemical progression 87 percent with early salvage against 86 percent with adjuvant radiotherapy (hazard ratio 1.12, 95 percent confidence interval 0.65 t...
Biliary cohort ORR 51% (22/43, investigator) and 47% (independent review); grade 3 or worse GGT rise 12%.
No chemo benefit postmenopausal; iDFS HR 0.60 with chemo premenopausal.
PFS HR 0.33 (ep), 0.49 (p).
Abdominal recurrence-free survival not improved by preoperative radiotherapy; possible benefit in liposarcoma subgroups only.
Continuous cohort reporting: positive signals for pembrolizumab in high tumour mutational burden cancers and trastuzumab plus pertuzumab in ERBB2-amplified colorectal cancer; palbo...
Five-year local recurrence 2.11 percent with single-dose intraoperative radiotherapy against 0.95 percent with external beam, meeting the 2.5 percent non-inferiority margin; at a m...
Median event-free survival 1,440 days with deferasirox against 1,091 days with placebo (hazard ratio 0.636, p 0.015).
Progression-free survival 2 of 19.2 against 16.4 months (hazard ratio 0.74).
hCG normalisation in 8 of 15 women (53 percent) with single-agent chemotherapy-resistant disease, none of whom relapsed; grade 1 to 2 adverse events in 93 percent and no treatment-...
OS 14.7 vs 9.6 months, HR 0.66; CR 36.7% vs 17.9%.
Independent-review objective response 46% (95% CI 36 to 57) among 99 patients with at least nine months of follow-up; median duration of response 11.1 months (Paik, NEJM 2020).
PFS HR 1.25 (negative).
High objective and complete response rates with durable remissions in mantle cell lymphoma after BTK inhibitor failure; approved in July 2020.
The publication year on key paper records.
Depil S, Duchateau P, Grupp SA, et al. Nature Reviews Drug Discovery.
Sahai E, Astsaturov I, Cukierman E, et al. Nature Reviews Cancer.
Kurtzberg J, Abdel-Azim H, Carpenter P, et al. Biology of Blood and Marrow Transplantation.
Tam CS, Opat S, D'Sa S, et al. Blood.
Goldman JW, Mazieres J, Barlesi F, et al. Frontiers in oncology.
Hayashi A, Fan J, Chen R, et al. Nature Cancer.
Dunsmore KP, Winter SS, Devidas M, et al. Journal of Clinical Oncology.
Aplenc R, Meshinchi S, Sung L, et al. Haematologica.
Reddy AT, Strother DR, Judkins AR, et al. Journal of Clinical Oncology.
Krown SE, Moser CB, MacPhail P, et al. The Lancet.
Timbergen MJM, Schut AW, Grünhagen DJ, et al. European Journal of Cancer.
Wu YL, Tsuboi M, He J, et al. New England Journal of Medicine.
Ascierto PA, Del Vecchio M, Mandalá M, et al. The Lancet Oncology.
Frühwald MC, Hasselblatt M, Nemes K, et al. Neuro-Oncology.
Rock CL, Thomson C, Gansler T, et al. CA: A Cancer Journal for Clinicians.
Mody R, Yu AL, Naranjo A, et al. Journal of Clinical Oncology.
Ramos CA, Grover NS, Beaven AW, et al. Journal of Clinical Oncology.
Nakamura Y, Namikawa K, Yoshino K, et al. Annals of Oncology.
Nagendran M, Chen Y, Lovejoy CA, et al. BMJ.
Radovich M, Jiang G, Hancock BA, et al. JAMA Oncology.
Molinaro AM, Hervey-Jumper S, Morshed RA, et al. JAMA Oncology.
Herbst RS, Giaccone G, de Marinis F, et al. New England Journal of Medicine.
Schmid P, Rugo HS, Adams S, et al. The Lancet Oncology.
Gutzmer R, Stroyakovskiy D, Gogas H, et al. The Lancet.
Yamamoto K, Venida A, Yano J, et al. Nature.
Petitprez F, de Reyniès A, Keung EZ, et al. Nature.
Shah N, Chari A, Scott E, et al. Leukemia.
Garcia J, Hurwitz HI, Sandler AB, et al. Cancer treatment reviews.
Redman MW, Papadimitrakopoulou VA, Minichiello K, et al. The Lancet Oncology.
Italiano A, Mir O, Mathoulin-Pelissier S, et al. The Lancet Oncology.
Laconi E, Marongiu F, DeGregori J. British Journal of Cancer.
Mathur P, Sathishkumar K, Chaturvedi M, et al. JCO Global Oncology.
Bolton KL, Ptashkin RN, Gao T, et al. Nature Genetics.
Schmid P, Abraham J, Chan S, et al. Journal of Clinical Oncology.
Wolf J, Seto T, Han JY, et al. New England Journal of Medicine.
Burn J, Sheth H, Elliott F, et al. The Lancet.
Malouff TD, Mahajan A, Krishnan S, et al. Frontiers in oncology.
Migden MR, Khushalani NI, Chang ALS, et al. The Lancet Oncology.
Bear AS, Vonderheide RH, O'Hara MH. Cancer Cell.
Guckenberger M, Lievens Y, Bouma AB, et al. The Lancet Oncology.
Turner NC, Kingston B, Kilburn LS, et al. The Lancet Oncology.
Comstock CE, Gatsonis C, Newstead GM, et al. JAMA.
Cortés-Ciriano I, Lee JJ, Xi R, et al. Nature Genetics.
Ben-David U, Amon A. Nature reviews. Genetics.
Fitzgerald RC, di Pietro M, O'Donovan M, et al. The Lancet.
Salama AKS, Li S, Macrae ER, et al. Journal of Clinical Oncology.
Subbiah V, Lassen U, Élez E, et al. The Lancet Oncology.
Patel SP, Othus M, Chae YK, et al. Clinical Cancer Research.
Shen S, Chen X, Cai J, et al. JAMA Oncology.
Lievens Y, Guckenberger M, Gomez D, et al. Radiotherapy and Oncology.
Shitara K, Bang YJ, Iwasa S, et al. New England Journal of Medicine.
Hiraoka N, Nitta H, Ohba A, et al. Human Pathology.
Lennon AM, Buchanan AH, Kinde I, et al. Science.
Ambrosone CB, Zirpoli GR, Hutson AD, et al. Journal of Clinical Oncology.
Rizvi NA, Cho BC, Reinmuth N, et al. JAMA Oncology.
Lonial S, Jacobus S, Fonseca R, et al. Journal of Clinical Oncology.
Reardon DA, Brandes AA, Omuro A, et al. JAMA Oncology.
Nanda R, Liu MC, Yau C, et al. JAMA Oncology.
Yau T, Kang YK, Kim TY, et al. JAMA Oncology.
Yang Y, Wang Z, Fang J, et al. Journal of Thoracic Oncology.
Clover AJP, de Terlizzi F, Bertino G, et al. European Journal of Cancer.
Sharman JP, Egyed M, Jurczak W, et al. The Lancet.
Doebele RC, Drilon A, Paz-Ares L, et al. The Lancet Oncology.
Drilon A, Siena S, Dziadziuszko R, et al. The Lancet Oncology.
Goyal G, Heaney ML, Collin M, et al. Blood.
Voss M, Wagner M, von Mettenheim N, et al. International Journal of Radiation Oncology, Biology, Physics.
Merino DM, McShane LM, Fabrizio D, et al. Journal for ImmunoTherapy of Cancer.
Wouters OJ, McKee M, Luyten J. JAMA.
Hochhaus A, Baccarani M, Silver RT, et al. Leukemia.
de Groot S, Lugtenberg RT, Cohen D, et al. Nature Communications.
Abou-Alfa GK, Sahai V, Hollebecque A, et al. The Lancet Oncology.
Kloor M, Reuschenbach M, Pauligk C, et al. Clinical Cancer Research.
Hassan R, Blumenschein GR, Moore KN, et al. Journal of Clinical Oncology.
Shaw AT, Bauer TM, de Marinis F, et al. New England Journal of Medicine.
Dummer R, Hauschild A, Santinami M, et al. New England Journal of Medicine.
Oaknin A, Tinker AV, Gilbert L, et al. JAMA Oncology.
Smyth EC, Nilsson M, Grabsch HI, et al. The Lancet.
O'Kane GM, Grunwald BT, Jang GH, et al. Clinical Cancer Research.
Noronha V, Patil VM, Joshi A, et al. Journal of Clinical Oncology.
Noe M, Niknafs N, Fischer CG, et al. Nature Communications.
Chen J, Yang H, Teo ASM, et al. Nature Genetics.
Park W, Chen J, Chou JF, et al. Clinical Cancer Research.
Mateo J, Seed G, Bertan C, et al. Journal of Clinical Investigation.
Wen PY, Weller M, Lee EQ, et al. Neuro-Oncology.
Global Retinoblastoma Study Group, Fabian ID, Abdallah E, et al. JAMA Oncology.
Filippini T, Malavolti M, Borrelli F, et al. The Cochrane database of systematic reviews.
Lin NU, Borges V, Anders C, et al. Journal of Clinical Oncology.
Murthy RK, Loi S, Okines A, et al. New England Journal of Medicine.
Hill JA, Seo SK. Blood.
Klichinsky M, Ruella M, Shestova O, et al. Nature Biotechnology.
Murray Brunt A, Haviland JS, Wheatley DA, et al. The Lancet.
Finn RS, Qin S, Ikeda M, et al. New England Journal of Medicine.
Rubin MA, Bristow RG, Thienger PD, et al. Molecular cell.
Mateos MV, Kumar S, Dimopoulos MA, et al. Blood cancer journal.
Pyo JS, Son BK, Lee HY, et al. Journal of Clinical Medicine.
Pandey A, Stawiski EW, Durinck S, et al. Nature Communications.
Rao S, Sclafani F, Eng C, et al. Journal of Clinical Oncology.
Poortmans PM, Weltens C, Fortpied C, et al. The Lancet Oncology.
Blay JY, Serrano C, Heinrich MC, et al. The Lancet Oncology.
Powles T, Park SH, Voog E, et al. New England Journal of Medicine.
Katai H, Mizusawa J, Katayama H, et al. The Lancet Gastroenterology and Hepatology.
Wells DK, van Buuren MM, Dang KK, et al. Cell.
Shitara K, Van Cutsem E, Bang YJ, et al. JAMA Oncology.
Marabelle A, Le DT, Ascierto PA, et al. Journal of Clinical Oncology.
Andre T, Shiu KK, Kim TW, et al. New England Journal of Medicine.
Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Journal of Clinical Oncology.
Grob JJ, Gonzalez R, Basset-Seguin N, et al. Journal of Clinical Oncology.
Schirripa M, Nappo F, Cremolini C, et al. Clinical Colorectal Cancer.
Rennert RC, Khan U, Bartek J, et al. Neurosurgery.
Li T, Fu J, Zeng Z, et al. Nucleic Acids Research.
Drilon A, Oxnard GR, Tan DSW, et al. New England Journal of Medicine.
Argilés G, Tabernero J, Labianca R, et al. Annals of Oncology.
Vaidya JS, Bulsara M, Baum M, et al. BMJ.
Logsdon GA, Vollger MR, Eichler EE. Nature reviews. Genetics.
Eichenauer DA, Plütschow A, Fuchs M, et al. Journal of Clinical Oncology.
Patil V, Noronha V, Dhumal SB, et al. The Lancet Global Health.
Fenaux P, Platzbecker U, Mufti GJ, et al. New England Journal of Medicine.
Centore RC, Sandoval GJ, Soares LMM, et al. Trends in genetics.
Roeland EJ, Bohlke K, Baracos VE, et al. Journal of Clinical Oncology.
Tung NM, Boughey JC, Pierce LJ, et al. Journal of Clinical Oncology.
Hassett MJ, Somerfield MR, Baker ER, et al. Journal of Clinical Oncology.
Goggins M, Overbeek KA, Brand R, et al. Gut.
Zucca E, Arcaini L, Buske C, et al. Annals of Oncology.
Elad S, Cheng KKF, Lalla RV, et al. Cancer.
Sohal DPS, Kennedy EB, Cinar P, et al. Journal of Clinical Oncology.
Kurata K, Kubo M, Kai M, et al. Breast Cancer.
León-Castillo A, de Boer SM, Powell ME, et al. Journal of Clinical Oncology.
Flaherty KT, Gray RJ, Chen AP, et al. Journal of Clinical Oncology.
Johnston SRD, Harbeck N, Hegg R, et al. Journal of Clinical Oncology.
Hanna TP, King WD, Thibodeau S, et al. BMJ.
Hu Z, Li Z, Ma Z, et al. Nature Genetics.
Heinrich MC, Jones RL, von Mehren M, et al. The Lancet Oncology.
de Koning HJ, van der Aalst CM, de Jong PA, et al. New England Journal of Medicine.
Mittendorf EA, Zhang H, Barrios CH, et al. The Lancet.
Goetze TO, Bechstein WO, Bankstahl US, et al. BMC Cancer.
Chalabi M, Fanchi LF, Dijkstra KK, et al. Nature Medicine.
Saura C, Oliveira M, Feng YH, et al. Journal of Clinical Oncology.
Azad NS, Gray RJ, Overman MJ, et al. Journal of Clinical Oncology.
Brown PD, Gondi V, Pugh S, et al. Journal of Clinical Oncology.
O'Reilly EM, Lee JW, Zalupski M, et al. Journal of Clinical Oncology.
Kelly CM, Antonescu CR, Bowler T, et al. JAMA Oncology.
Domchek SM, Postel-Vinay S, Im SA, et al. The Lancet Oncology.
Stopsack KH, Nandakumar S, Wibmer AG, et al. Clinical Cancer Research.
Szpakowski JL, Tucker LY. JAMA Network Open.
Phillips R, Shi WY, Deek M, et al. JAMA Oncology.
Maniakas A, Dadu R, Busaidy NL, et al. JAMA Oncology.
Pishvaian MJ, Blais EM, Brody JR, et al. The Lancet Oncology.
Ramalingam SS, Vansteenkiste J, Planchard D, et al. New England Journal of Medicine.
Ahn ER, Mangat PK, Garrett-Mayer E, et al. JCO Precision Oncology.
Schmid P, Cortes J, Pusztai L, et al. New England Journal of Medicine.
Geoerger B, Kang HJ, Yalon-Oren M, et al. The Lancet Oncology.
Cortes J, Cescon DW, Rugo HS, et al. The Lancet.
Shen S, Vagner S, Robert C. Cell.
Nia HT, Munn LL, Jain RK. Science.
Chera BS, Kumar S, Shen C, et al. Journal of Clinical Oncology.
Burd A, Levine RL, Ruppert AS, et al. Nature Medicine.
Versteijne E, Suker M, Groothuis K, et al. Journal of Clinical Oncology.
Barroso-Sousa R, Jain E, Cohen O, et al. Annals of Oncology.
Vokinger KN, Hwang TJ, Grischott T, et al. The Lancet Oncology.
Autio KA, Boni V, Humphrey RW, et al. Clinical Cancer Research.
de Bono J, Mateo J, Fizazi K, et al. New England Journal of Medicine.
Cavallone L, Aguilar-Mahecha A, Lafleur J, et al. Scientific Reports.
Hofman MS, Lawrentschuk N, Francis RJ, et al. The Lancet.
Rashid NU, Peng XL, Jin C, et al. Clinical Cancer Research.
Wei AH, Döhner H, Pocock C, et al. New England Journal of Medicine.
Parker CC, Clarke NW, Cook AD, et al. The Lancet.
Van Cutsem E, Tempero MA, Sigal D, et al. Journal of Clinical Oncology.
de Savornin Lohman EAJ, van der Geest LG, de Bitter TJJ, et al. Annals of Surgical Oncology.
Sato J, Satouchi M, Itoh S, et al. The Lancet Oncology.
Patil VM, Bhelekar A, Menon N, et al. Cancer Medicine.
Minard-Colin V, Aupérin A, Pillon M, et al. New England Journal of Medicine.
Monje M, Borniger JC, D'Silva NJ, et al. Cell.
Gisslinger H, Klade C, Georgiev P, et al. The Lancet Haematology.
Baine MK, Hsieh MS, Lai WV, et al. Journal of Thoracic Oncology.
Miles LA, Bowman RL, Merlinsky TR, et al. Nature.
Machiels JP, René Leemans C, Golusinski W, et al. Annals of Oncology.
Palma DA, Olson R, Harrow S, et al. Journal of Clinical Oncology.
Bonvalot S, Gronchi A, Le Péchoux C, et al. The Lancet Oncology.
Lei J, Ploner A, Elfström KM, et al. New England Journal of Medicine.
Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Journal of Clinical Oncology.
Gounder M, Schöffski P, Jones RL, et al. The Lancet Oncology.
Nagtegaal ID, Odze RD, Klimstra D, et al. Histopathology.
Arvanitis CD, Ferraro GB, Jain RK. Nature Reviews Cancer.
Chicago Consensus Working Group. Cancer.
Phan TG, Croucher PI. Nature Reviews Cancer.
Sledge GW, Toi M, Neven P, et al. JAMA Oncology.
Prior IA, Hood FE, Hartley JL. Cancer Research.
Rieke N, Hancox J, Li W, et al. NPJ digital medicine.
Schoenfeld AJ, Bandlamudi C, Lavery JA, et al. Clinical Cancer Research.
Braendstrup P, Levine BL, Ruella M. Cytotherapy.
Middleton G, Fletcher P, Popat S, et al. Nature.
Alexandrov LB, Kim J, Haradhvala NJ, et al. Nature.
Zhang WH, Zhang SY, Hou QQ, et al. Frontiers in oncology.
Ho WJ, Jaffee EM, Zheng L. Nature Reviews Clinical Oncology.
Yoshida K, Gowers KHC, Lee-Six H, et al. Nature.
Cloughesy TF, Petrecca K, Walbert T, et al. JAMA Oncology.
Chan-Seng-Yue M, Kim JC, Wilson GW, et al. Nature Genetics.
Modi S, Saura C, Yamashita T, et al. New England Journal of Medicine.
Abida W, Patnaik A, Campbell D, et al. Journal of Clinical Oncology.
You B, Bolze PA, Lotz JP, et al. Journal of Clinical Oncology.
Barroso-Sousa R, Keenan TE, Pernas S, et al. Clinical Cancer Research.
Benjamin R, Graham C, Yallop D, et al. The Lancet.
Bareche Y, Buisseret L, Gruosso T, et al. JNCI: Journal of the National Cancer Institute.
Mok T, Camidge DR, Gadgeel SM, et al. Annals of Oncology.
Liu E, Marin D, Banerjee P, et al. New England Journal of Medicine.
DiNardo CD, Jonas BA, Pullarkat V, et al. New England Journal of Medicine.
Paik PK, Felip E, Veillon R, et al. New England Journal of Medicine.
Wang M, Munoz J, Goy A, et al. New England Journal of Medicine.
The history entries editors wrote on cancer records: the dated turning points of each disease.
High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)
Atypical teratoid/rhabdoid tumour (ATRT). COG phase 3 with high-dose chemotherapy and autologous rescue (JCO 2020).
SHH-activated medulloblastoma
Kaposi sarcoma
Resectable stage I to III non-small-cell lung cancer
Non-small-cell lung cancer
EGFR-mutated non-small-cell lung cancer
Adult granulosa cell tumour of the ovary
Non-metastatic castration-resistant prostate cancer
Angiosarcoma
Salivary duct carcinoma
Metastatic triple-negative breast cancer
Male breast cancer. First ASCO guideline on male breast cancer; FDA guidance on including men in breast cancer drug development.
Triple-negative breast cancer (TNBC). ER 1 to 10 percent is reported separately because endocrine benefit is uncertain; cohorts show these tumours behave like triple-negative disea...
Gastrointestinal stromal tumour (GIST)
Bladder & urothelial cancer
Multiple myeloma
Mantle cell lymphoma. First CAR-T for MCL: 93% response after BTKi failure.
Pancreatic ductal adenocarcinoma. Goal: high-grade dysplasia and T1N0M0 cancer; EUS and MRI/MRCP yearly; ATM carriers with an affected relative now eligible.
Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)
Head and neck squamous cell carcinoma
Glioma & glioblastoma. CheckMate 548 (2022) and CheckMate 498 (2023) follow in newly diagnosed disease; all three negative.
Pleural mesothelioma
Mesothelioma
HPV-positive oropharyngeal cancer
ALK-positive non-small-cell lung cancer
Acute lymphoblastic leukaemia. Dasatinib then blinatumomab, 18-month OS 95%.
Extrapulmonary neuroendocrine carcinoma
Platinum-sensitive ovarian cancer
Desmoid tumour. Active surveillance as initial management for most patients (Eur J Cancer).
HER2-positive gastric cancer
Smouldering multiple myeloma
Tenosynovial giant cell tumour (TGCT). Hepatotoxicity judged to outweigh benefit for a non-lethal disease.
Epithelioid sarcoma. Doxorubicin with or without tazemetostat, first line (NCT04204941).
Breast cancer (all types). 26 Gy in five fractions non-inferior to 40 Gy in fifteen at five years; adopted across the United Kingdom and accelerated by the pandemic.
BRAF V600E-mutant colorectal cancer
Intrahepatic cholangiocarcinoma
Acute myeloid leukaemia in children
MET exon 14 and MET-amplified non-small-cell lung cancer
Retinoblastoma
HER2-low and HER2-ultralow metastatic breast cancer
HER2-positive breast cancer with brain metastases
Brain metastases (secondary brain tumours)
Pancreatic ductal adenocarcinoma. Core and biallelic repair-gene mutations predict first-line platinum benefit (hazard ratio 0.44); single-cell sequencing adds antigen-presenting f...
Hepatocellular carcinoma. First regimen to improve OS over sorafenib; new standard.
Advanced hepatocellular carcinoma (BCLC C)
Hepatocellular carcinoma
BRAF V600-mutant melanoma
Burkitt lymphoma. Minard-Colin and colleagues (NEJM 2020).
Metastatic and recurrent anal squamous cell carcinoma
Anal cancer (squamous cell carcinoma)
Imatinib-resistant GIST
Acral melanoma
HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
Early gastric cancer
Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma
Colorectal cancer
Mismatch-repair deficient (MSI-high) colorectal cancer
Hodgkin lymphoma
Early triple-negative breast cancer
Advanced cutaneous squamous cell carcinoma
Recurrent and metastatic nasopharyngeal carcinoma
Small-cell lung cancer
Extensive-stage small-cell lung cancer
Myelodysplastic syndromes / neoplasms (MDS). MEDALIST in ring-sideroblast MDS after ESA failure; COMMANDS (2023) moves it to first line.
Lower-risk myelodysplastic syndromes
Esthesioneuroblastoma (olfactory neuroblastoma)
Anaplastic thyroid cancer
HR-positive / HER2-negative breast cancer
High-risk early HR-positive breast cancer
PDGFRA D842V-mutant GIST
Neuroblastoma (paediatric)
High-risk neuroblastoma
Lung cancer (all types). Volume CT at baseline and years 1, 3 and 5.5 in 13,195 men and 2,594 women aged 50 to 74 in the Netherlands and Belgium: a lung cancer death rate ratio of...
Colorectal cancer. One guideline for colorectal cancer from Lynch syndrome prevention to follow-up, alongside the BSG, ACPGBI and Public Health England rules that decide who gets a...
Mesothelioma
Brain metastases (secondary brain tumours)
Higher-risk myelodysplastic syndromes
Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms
Buccal mucosa and gingivobuccal cancer (oral cancer in India)
Triple-negative breast cancer (TNBC). KEYNOTE-355 in CPS ≥10 disease.
Cutaneous squamous cell carcinoma
Non-muscle-invasive bladder cancer
Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)
Biliary tract cancer (cholangiocarcinoma)
Biliary tract cancer (all types)
Biliary tract cancer (cholangiocarcinoma)
Chondrosarcoma
Kaposi sarcoma
Chordoma. WHO classification of soft tissue and bone tumours, fifth edition.
p53-abnormal endometrial cancer, including uterine serous carcinoma
POLE-ultramutated endometrial cancer
Triple-negative breast cancer (TNBC). BRE12-158's preplanned analysis of 196 residual-disease patients: distant relapse hazard ratio 2.99 and death hazard ratio 4.16 when ctDNA is...
Pancreatic ductal adenocarcinoma. Preoperative chemoradiotherapy: 16.0 versus 14.3 months, R0 71 versus 40 percent. Pegvorhyaluronidase: 11.2 versus 11.5 months.
Resectable pancreatic ductal adenocarcinoma
Borderline resectable pancreatic ductal adenocarcinoma
Metastatic castration-resistant prostate cancer
Localised prostate cancer, high and very high risk
Biochemical recurrence of prostate cancer
Prostate cancer
Prostate cancer. In 302 randomised men, PSMA PET-CT is 27% more accurate than CT with bone scan, changes management twice as often and delivers less than half the radiation.
Rectal cancer
Thymic carcinoma
Thymoma and thymic carcinoma
Sarcomas (soft tissue, bone, GIST)
Metastatic cancer (cancer that has spread). Five-year survival more than doubles with stereotactic radiotherapy to all metastases in the randomised phase 2 trial.
Triple-negative breast cancer (TNBC). ASCENT: OS 12.1 vs 6.7 months in pretreated disease; first ADC for TNBC.
Neuroendocrine tumours
RET fusion-positive non-small-cell lung cancer
Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)
Thyroid cancer
Thyroid cancer
Medullary thyroid cancer
Malignant peripheral nerve sheath tumour (MPNST)
Retroperitoneal sarcoma
Liposarcoma
Rare cancers of childhood (NCI PDQ umbrella)
Diffuse large B-cell lymphoma
Recurrent or metastatic head and neck squamous cell carcinoma
Epithelioid sarcoma. FDA, 23 January 2020, based on EZH-202 (Gounder and colleagues, Lancet Oncol 2020).
Atypical teratoid/rhabdoid tumour (ATRT). First EZH2 inhibitor approval; paediatric rhabdoid tumour responses in the phase 1 programme.
Gallbladder cancer. 167 tumours from Korea, India and Chile: ELF3 frameshift neoantigens, CTNNB1, STK11 and Wnt alterations (Pandey et al., Nature Communications).
Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)
Gestational trophoblastic neoplasia
HER2-positive breast cancer
Acute myeloid leukaemia in older or unfit patients
Acute myeloid leukaemia. OS 14.7 vs 9.6 months; full approval October 2020; oral azacitidine maintenance approved (QUAZAR).
HPV-independent vulvar squamous cell carcinoma (p53-mutant)
HPV-associated vulvar squamous cell carcinoma
Mucinous ovarian cancer
Cervical cancer. Swedish registry study shows ~88% cancer reduction in women vaccinated before 17.
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Watertown, MA
Eindhoven
Larkspur, California
San Diego, CA
Wuxi
Boston, MA
Rockville, MD
Boston, MA
Nashville, TN
Pittsburgh, PA
The funding rounds on company records, each with the source that states the figure.
$7m. Total sold per Form D filed August 2020
$72m. 4,000,000 shares at $18.00 on the Nasdaq Global Market, priced 28 October 2020; gross proceeds before underwriting discounts.
$231m. 12,174,263 shares including full over-allotment; gross proceeds 231.3 million US dollars, completed February 2020
$15m. Equity offering first sold 30 January 2020; USD 15.0 million sold of USD 18.0 million, including USD 7.5 million of converted notes
EUR 6.1 million late seed round led by Industrifonden, January 2020 (as listed on the company news page).
$135m. 7.5 million shares at 16 US dollars in October 2020 plus 951,837 option shares in November 2020; gross proceeds 135.2 million US dollars
$19m. Expanded Series A led by Gurnet Point Capital, December 2020.
Company states it became part of Boehringer Ingelheim in 2020; deal value not stated on the fetched page
$6m. Company page dated November 2020; investors not named on the page
$28m. Led by Baird Capital
$192m. Equity offering by Orca BioSystems Inc, first sale 29 November 2019, filed July 2020
$138m. 8,625,000 shares at 16 US dollars including full exercise of the underwriters' option; closed 28 April 2020
$5m. Round not named by the company; led by Asset Management Ventures and included National Cancer Institute federal funds
$182m. Gross proceeds of about 181.9 million US dollars, September 2020
$400m. Final prospectus: 20 million shares at 20 US dollars per share, before the underwriters' option of up to 3 million additional shares
$25m. Total sold per Form D filed May 2020
$147m. Total sold per Form D filed December 2020
$62m
$190m. 10,557,000 shares at 18 US dollars in April 2020; gross proceeds about 190 million US dollars
The founded year on journal records.
American Association for Cancer Research
Springer Nature
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Journal of Medical Radiation Sciences
Eur J Cancer
JCO
The Lancet Oncology
Journal of Medical Imaging and Radiation Oncology
International Journal of Laboratory Hematology
The Lancet Oncology
Lancet
Lancet Oncology
The Lancet Oncology
Nature Reviews Cancer
Nature
Journal of Neuroimmunology
Cells
European Journal of Hybrid Imaging
JAMA
NEJM
Lancet
Journal of Palliative Medicine
NEJM
Seminars in Oncology
NEJM
Scandinavian Journal of Immunology
Lancet Oncology
Chinese Clinical Oncology
Critical Care
Lancet Oncology
ecancermedicalscience
Lancet
NEJM
Pediatric Blood & Cancer
Lancet
Nature Medicine
Cancer Immunology, Immunotherapy
Acta Clin Croat
Indian Journal of Surgical Oncology
Lancet Oncology
Blood
Journal of Thoracic Oncology
J Am Coll Cardiol
Bulletin du Cancer
New England Journal of Medicine
New England Journal of Medicine
Frontiers in Immunology
Economía de la Salud
Journal of Thoracic Disease
Nature Cancer
Lancet Oncology
Nature Reviews Clinical Oncology
JAMA
European Journal of Cancer
International Journal of Dermatology
Cancer Medicine
JCO
NEJM
New England Journal of Medicine
Lancet Oncology
Journal for ImmunoTherapy of Cancer
Nature Communications
Annals of Oncology
Annals of Oncology
The Lancet Global Health
Journal of Clinical Oncology
Nature Communications
BMC Research Notes
Annals of Oncology
Nat Med
Science
Frontiers in Immunology
Lancet
Gynecologic Oncology
Liver Cancer
Journal of Clinical Oncology
Frontiers in Microbiology
Blood Advances
Molecular Cancer Research
Virchows Archiv
Cardiovasc Toxicol
British Journal of Haematology
Biomed Pharmacother
Nature
Cell
Journal of Clinical Oncology
Lancet Oncology
Lancet Oncol
NEJM
The Lancet Oncology
Cells
Chinese Clinical Oncology
Cancers
JCO
NEJM
Therapeutic Advances in Hematology
Lancet Oncology
NEJM
Frontiers in Oncology
Critical Reviews in Oncology/Hematology
Surgical Oncology Clinics of North America
The Lancet
Blood Cancer Journal
Radiotherapy and Oncology
JCO
Clinical Cancer Research
Journal of Clinical Oncology
JCO
International Journal of Surgery Case Reports
American Journal of Perinatology
ESMO Open
Lancet Oncology
NEJM
JCO Global Oncology
Oral Oncology
NEJM
Current Oncology
New England Journal of Medicine
NEJM
Clinical Lymphoma Myeloma and Leukemia
Cancer Immunology, Immunotherapy
Clinical Cancer Research
Nature Cancer
BMC Biol
NEJM
NEJM
Lancet Oncology
Breast Care
Journal for ImmunoTherapy of Cancer
Journal of Clinical Oncology
Eur Arch Otorhinolaryngol
The Oncologist
JCO Glob Oncol
Clinical Cancer Research
Genetics
Gastroenterology
Lancet
European Urology
Lancet Oncology
Clinical Cancer Research
International Journal of Gynecological Cancer
Journal of Clinical Oncology
Journal of Gastroenterology
Annals of Surgical Oncology
Biomaterials
NEJM
Nature Reviews Molecular Cell Biology
Tumori Journal
The Lancet Oncology
The Lancet Oncology
Nature Medicine
Cancer Immunology, Immunotherapy
New England Journal of Medicine
J Clin Oncol
British Journal of Cancer
Nature Communications
JAMA Oncology
Clinical and Translational Radiation Oncology
Cancer Cell
Lancet Haematology
BMJ Case Reports
The Lancet Oncology
Ann Surg
NEJM
Nature Reviews Clinical Oncology
Nature Medicine
JCO
Nature Reviews Clinical Oncology
World Journal of Urology
J Hematol Oncol
Nature
The Lancet Child & Adolescent Health
NEJM
NEJM
Annals of Oncology
Journal of Hematology & Oncology
Cancer Immunology Research
Clinical Cancer Research
The Lancet
Cancer Discovery
JMIR Public Health and Surveillance
European Urology
Clinical and Translational Oncology
Lancet
Lancet Oncology
Blood
Lancet Oncology
Journal of Clinical Oncology
European Journal of Cancer